Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib

Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib

Background: Although lenvatinib was recently approved for treatment of advanced unresectable hepatocellular carcinoma (HCC) based on the phase III REFLECT trial, no biomarkers for management of lenvatinib treatment have been established. The aim of this study is to identify predictive biomarkers for...

Full description

Bibliographic Details
Main Authors: Atsushi Ono, Hiroshi Aikata, Masami Yamauchi, Kenichiro Kodama, Waka Ohishi, Takeshi Kishi, Kazuki Ohya, Yuji Teraoka, Mitsutaka Osawa, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Daiki Miki, Tomokazu Kawaoka, Hiromi Abe-Chayama, Peiyi Zhang, Songyao Liu, Grace Naswa Makokha, Masataka Tsuge, Michio Imamura, C. Nelson Hayes, Kazuaki Chayama
Format: Article
Language:English
Published: SAGE Publishing 2020-05-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835920922051

Internet

https://doi.org/10.1177/1758835920922051

Similar Items